^
Association details:
| Biomarker: | ALK fusion + ALK G1202R |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report
Published date:
07/12/2022
Excerpt:
We present the case of a 26-year-old man who was diagnosed with ALK-positive extensive-stage SCLC...After 2 cycles of Alectinib, the CT scan showed a partial response. However, after 9 cycles of treatment, a metastatic lesion enlarged and a new brain lesion appeared....NGS analysis of a series of liquid biopsies revealed a new mutation, ALK p.G1202R, which resulted in resistance to Alectinib... The patient is currently receiving Anlotinib in combination with CPT-11 and is stable with an OS of more than 18 months.
Secondary therapy:
irinotecan
